Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Childhood Leukemia | Kisho | Kisho

Back to Childhood Leukemia

Childhood Leukemia — NIH Grants & Funding

Active and recent NIH-funded research on Childhood Leukemia. Data from NIH RePORTER, last 36 months.

MONDO:0004355

NIH-funded research on Childhood Leukemia

active grants

institutions

100

researchers

new in last 12 mo.

$227.1M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(30)

Basic ScienceR01Active

Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia

Loh, Mignon et al.·SEATTLE CHILDREN'S HOSPITAL·SEATTLE, WA

$3,480,276 (FY2025)

Childhood Leukemia — NIH Grants & Funding

Basic Science(30)

Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia

Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell

Cytomegalovirus as an etiologic and clinico-pathogenic factor in childhood acute lymphoblastic leukemia

A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia

Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival

An Accurate Machine Learning Framework for Childhood Acute Myeloid Leukemia Subtype Identification by Integrating Bulk and Single-Cell Multi-Omics Data Within and Beyond the CCDI Ecosystem

Repeat enhancers as drivers of ETV6-RUNX1+ and ETV6-RUNX1-like B-lymphoblastic leukemia

Investigating and targeting NSD2 mutation-driven leukemia transformation

Elucidate the Role of RNA Editing in Acute T-cell Lymphoblastic Leukemia Initiating Cells

Molecular Pathogenesis of AF10-Rearranged Leukemias

Translational(11)

Specialized Program of Research Excellence (SPORE) in Leukemia

Novel targeted therapy to reduce health disparities in pediatric leukemia

Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia

Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia

Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia

Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia

Overcoming Leukemia Chemoresistance in the Central Nervous System

Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia

Elucidating Critical Dependencies Underlying Therapeutic Evasion in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)

Clinical(17)

A compass for those with relapsed leukemia after transplant

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia

Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia

NCI Pediatric In Vivo Testing Program - Leukemia

Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications

Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML.

Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease

T cell acute lymphoblastic leukemia entry into the central nervous system

COG NCTN Network Group Operations Center Year 11 Extension

Children's Oncology Group Statistics and Data Center

Epi / Nat. History(11)

Prevalence and persistence of the ETV6/RUNX1 pre-leukemic clone

A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia

Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos

Support For Infrastructure of Childhood Leukemia Environmental Research

Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos

Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium

An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia.

Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic Leukemia

Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL

Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study

Gene/Cell Therapy(11)

Targeting MicroRNAs to Eradicate Leukemia Stem Cells

Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia

Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia

Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)

Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy

Activating Low-Affinity T Cells to Prevent Relapse in Acute Lymphoblastic Leukemia

Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy

Cassette exons in neoplastic pro-B-cells: implications for immunotherapy

CONCEPT SBIR - T-CELL RECEPTORS FOR TREATING PEDIATRIC ACUTE MYELOID LEUKEMIA

Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia

Biomarker / Dx(1)

Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia

Other(2)

Clinical Trials Specialist in Developmental Therapeutics

Clinician Scientist in Leukemia